Spero Therapeutics, Inc. Annual Revenues in USD from 2016 to 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).
Summary
Spero Therapeutics, Inc. quarterly/annual Revenues history and growth rate from 2016 to 2023.
  • Spero Therapeutics, Inc. Revenues for the quarter ending September 30, 2024 was $13.5M, a 47.1% decline year-over-year.
  • Spero Therapeutics, Inc. Revenues for the twelve months ending September 30, 2024 was $106M, a 37% increase year-over-year.
  • Spero Therapeutics, Inc. annual Revenues for 2023 was $104M, a 94% increase from 2022.
  • Spero Therapeutics, Inc. annual Revenues for 2022 was $53.5M, a 193% increase from 2021.
  • Spero Therapeutics, Inc. annual Revenues for 2021 was $18.3M, a 95.7% increase from 2020.
Revenues, Trailing 12 Months (USD)
Revenues, Annual (USD)
Revenues, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 $104M +$50.3M +94% Jan 1, 2023 Dec 31, 2023 10-K 2024-03-13
2022 $53.5M +$35.3M +193% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-13
2021 $18.3M +$8.93M +95.7% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-30
2020 $9.33M -$8.82M -48.6% Jan 1, 2020 Dec 31, 2020 10-K 2022-03-31
2019 $18.1M +$14.2M +358% Jan 1, 2019 Dec 31, 2019 10-K 2021-03-11
2018 $3.97M +$1.99M +100% Jan 1, 2018 Dec 31, 2018 10-K 2020-03-16
2017 $1.98M +$1.64M +491% Jan 1, 2017 Dec 31, 2017 10-K 2019-03-14
2016 $335K Jan 1, 2016 Dec 31, 2016 10-K 2019-03-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.